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Context: The risk for dementia among obese subjects with normal metabolic profiles, so 
called metabolically healthy obese (MHO), remains uninvestigated.  
Objective: To determine the association between late-life metabolic health and obesity status 
and risk of incident dementia. 
Design: Retrospective cohort study. 
Setting: The National Health Insurance System, Republic of Korea. 
Patients: 12,296,863 adults over age 50 who underwent health examinations from 2009 to 
2012 without baseline history of dementia.  
Main Outcome Measure: Incident overall dementia, Alzheimer’s disease (AD), and 
vascular dementia (VaD).  
Results: Among population with age ≥60, 363,932 subjects (6.4%) developed dementia 
during a median follow up of 65 months (interquartile range [IQR] 51-74 months). The MHO 
group showed the lowest incidence of overall dementia (hazard ratio [HR] 0.85, 95% 
confidence interval [CI] 0.84-0.86) and AD (HR 0.87, 95% CI 0.86-0.88), but not VaD, 
compared to the metabolically healthy non-obese (MHNO) group. All components of 
metabolic syndrome except obesity significantly elevated the risk of dementia and these 
associations were more pronounced in VaD. Particularly, being underweight dramatically 
increased the risk of dementia.  
Conclusions: The MHO phenotype in late life demonstrated decreased risk of overall 
dementia and AD, but not VaD. Further studies in other populations are warranted to better 
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understand current results and may serve to predict individuals most at risk of developing 
dementia.   
This large, population-based study analyzed 5,669,488 adults over 60 and found that the 
metabolically healthy obese phenotype in late life is associated with lower risk of overall dementia. . 
Background 
As society ages, the prevalence of dementia increases. Currently, 35 million people are 
suffering from dementia, which is expected to double every 20 years (1, 2). Dementia is 
characterized by the coexistence of memory impairment and at least one cognitive functional 
deficit (3). It is also a contributing cause of death, as dementia is usually accompanied by 
immobility, malnutrition, and weight loss (4). Medical care costs for individuals with 
dementia are increasing and are substantially greater than those for cancer, heart disease, or 
other diseases (5). 
The most common type of dementia is Alzheimer’s disease (AD), which accounts for 
60%-80% of cases, followed by vascular dementia (VaD) (6). Aging, family history, 
apolipoprotein E4 phenotype, and lower educational level are well known risk factors for 
both AD and VaD (6, 7). In addition, recent evidence suggests both VaD and AD are closely 
related to cardiovascular risk factors such as hypertension, diabetes mellitus (DM), 
hyperlipidemia, and cigarette smoking (8-11). Regarding the association between obesity and 
dementia, midlife obesity is associated with an increased risk of dementia (12, 13), whereas 
in late life there is a reversed causation (13, 14).  
Recently, several studies suggested improvement in clinical outcomes among a subgroup 
of obese subjects with normal metabolic profiles despite increased adiposity, termed 
"metabolically healthy obese (MHO)" (15). These subjects exhibited lower insulin resistance, 
visceral adiposity, and were not at increased risk of cardiovascular disease (CVD) and all-
cause mortality compared to metabolically healthy non-obese (MHNO) subjects (15, 16). In 
contrast, with regard to the development of hypertension, type 2 DM, and chronic kidney 
disease (CKD), MHO subjects were at 1.4 to 1.6-fold higher risk compared to their non-obese 
counterparts (17-19). However, to our knowledge, there are no studies reporting the 
relationship between the MHO phenotype and the development of dementia. Therefore, we 
investigated the impact of the MHO phenotype on incident dementia according to body mass 
index (BMI) and metabolic health status, using a nationwide population-based cohort study. 
Materials and Methods 
Study population 
National Health Insurance (NHI) system of Korea consists of the two major programs: NHI 
(covers 97% of the population) and Medical Aid (MA, covers remaining 3% of the low-
income population). All Koreans must be registered in these two systems. Since 2006, 
database of MA beneficiaries has been integrated into a single National Health Insurance 
System (NHIS) (20, 21). The NHIS database contains demographic information (age, sex, 
income level, etc.), claims information (diagnosis defined by International Classification of 
Diseases [ICD] codes and details of prescriptions), and health check-up information (results 
of basic laboratory tests and questionnaires about past medical history, current medications, 
and lifestyle). The national health screening program of NHIS is recommended biannually, 
and the participation rate is high, recorded 74.8% in 2014 (20-22). In the current study, we 
used NHIS data, which is an well-established cohort representing the entire Korean 
population which is over 50 million. This study was approved by the Institutional Review 
Board of the Yonsei University Health System, Severance Hospital (No. 4-2016-0770) and 
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informed consent from study participants was waived due to the retrospective cohort nature 
of the study.    
We included subjects who underwent health examinations between January 1, 2009 and 
December 31, 2012. Of the 23,503,802 adults, subjects who had missing baseline data (n = 
195,777), age under 50 (n = 10,926,515), and those who diagnosed with dementia before the 
index period (n = 84,647) were excluded. A total of 12,296,863 participants were enrolled 
into the study and were followed for a median of 65 months (interquartile range [IQR] 51-74 
months). To determine the association between late-life metabolic health and obesity status 
and risk of incident dementia, 5,669,488 individuals aged 60 years or older were mainly 
analyzed and late middle-age group of 50-60 years (n = 6,627,375) was further analyzed in 
the supplementary analysis.  
Clinical and laboratory measurements  
As part of the health examinations, all subjects completed a questionnaire on their medical 
history, use of tobacco and alcohol, and exercise habits. Smoking habits were categorized as 
non-current or current; alcohol use was classified as <30 g per day or ≥30 g per day (heavy 
drinker); and exercise level was categorized as <3 times per week or ≥3 times of moderate to 
vigorous exercise per week (physically active). We defined low socioeconomic status as 
lowest 20% income status. BMI was calculated as body weight divided by height squared 
(kg/m2). Blood pressure (BP) was measured in the sitting position after 5 minutes of rest. 
After overnight fasting, blood samples were collected. Serum glucose, total cholesterol, 
triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) were 
measured. We calculated glomerular filtration rate (GFR) using the 4-variable Modification 
of Diet in Renal Disease Study Equation (23). Baseline comorbidities were identified as 
follows: hypertension (ICD-10 codes I10-13, I15 and treatment with anti-hypertensive 
medications, or systolic/diastolic BP ≥140/90 mmHg), type 2 DM (ICD-10 codes E11-E14 
and anti-diabetic drugs, or fasting glucose level ≥126 mg/dL), hyperlipidemia (ICD-10 code 
E78 with lipid-lowering agents, or serum total cholesterol ≥240 mg/dL), CKD (eGFR <60 
mL/min/1.73m2), previous myocardial infarction (MI; ICD-10 codes I21-I22) and ischemic 
stroke (ICD-10 codes I63-I64).  
Definition of incident dementia  
Incident dementia was considered to be a diagnosis of dementia (ICD-10 codes F00, G30, 
F01, F02, F03, G23.1, G31.0, G31.1, G31.82, G31.83, G31.88, and F10.7) and prescription 
of anti-dementia medication at the same time. The anti-dementia medications could include 
an acetylcholinesterase inhibitor (rivastigmine, galantamine, or aricept) or N-methyl-D-
aspartate (NMDA)-receptor antagonist (memantine), which are most commonly used for the 
treatment of dementia (24). Patients with dementia were grouped into AD (ICD-10 codes 
F00, G30) or VaD (ICD-10 code F01) by the diagnosis code at the first visit. If both 
diagnosis of AD and VaD were recorded at the first visit, we used the diagnosis of the second 
visit. 
Definitions of metabolic health and obesity status  
Obesity phenotypes were based on the Asia-Pacific BMI criteria (non-obese <25 kg/m2 or 
obese ≥25 kg/m2), which were established by the World Health Organization Western 
Pacific Region (25). To identify an individual as metabolically healthy, we used the Adult 
Treatment Panel-III (ATP-III) definition (26). The waist circumference (WC) criterion was 
not used due to its collinearity with BMI by adopting the definition of previous studies (19, 
27). Metabolically healthy was defined as meeting no more than one of the following four 
criteria: 1) a systolic BP ≥130 mmHg and/or diastolic BP ≥85 mmHg, or on anti-
hypertensive treatment; 2) TG ≥150 mg/dL; 3) fasting plasma glucose (FPG) ≥100 mg/dL or 
on antidiabetic treatment; 4) HDL-cholesterol <40 mg/dL in men and <50 mg/dL in women. 
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According to these criteria, participants were categorized as follows: 1) MHNO: BMI <25 
kg/m2 and <2 metabolic risk factors; 2) metabolically unhealthy non-obese (MUNO): BMI 
<25 kg/m2 and ≥2 metabolic risk factors; 3) MHO: BMI ≥25 kg/m2 and <2 metabolic risk 
factors; 4) metabolically unhealthy obese (MUO): BMI ≥25 kg/m2 and ≥2 metabolic risk 
factors.  
Statistical analysis  
All continuous variables are expressed as a mean (standard deviation), and categorical data 
are presented as numbers (percentages). The characteristics of study participants according to 
metabolic health and obesity status were compared using one-way analysis of variance for 
continuous variables and the chi-square test for categorical variables. Dementia-free survival 
curves were constructed using the Kaplan-Meier method, and between-group differences 
were compared using log-rank tests. Person-years of follow-up were calculated from the date 
of the health examination to the date of diagnosis of dementia or to December 31, 2016, 
whichever came first. Multivariate Cox proportional hazards regression analysis was 
performed to identify hazard ratios (HRs) of incident dementia according to metabolic health 
and obesity status: unadjusted in model 1, age and sex were adjusted in model 2, and tobacco 
and alcohol use, exercise habits, socioeconomic status, and LDL-cholesterol were further 
adjusted in model 3. The MHNO group was used as a reference, and results are presented as 
HR and 95% confidence interval (CI). Subgroup analyses were conducted by dividing the 
subjects according to the status of smoking, drinking, and exercise to adjust for the influence 
of modifiable risk factors, which were different in the baseline profiles among the four 
groups. We also conducted supplementary analyses: First, as being underweight is associated 
with vitamins and mineral deficiencies and as undetected subtle dementia may cause body 
weight loss, sensitivity analyses were conducted after exclusion of individuals with BMI 
under 18.5 kg/m2. Second, given the increasing incidence of dementia in younger individuals, 
we further analyzed the effect of metabolic health and obesity status on the development of 
dementia in subjects aged 50-60 years. All statistical analyses were performed using SAS 
version 9.2 (SAS Institute, Cary, NC, USA) and R programming version 3.1.0 (The R 
Foundation for Statistical Computing, Vienna, Austria, http:www.R-project.org). A P-value 
<0.05 was considered significant.  
Results 
Baseline characteristics of study subjects  
The baseline clinical and biochemical characteristics of the subjects are summarized in Table 
1. Among 5,669,488 participants aged over 60, 1,738,074 (30.7%), 1,852,845 (32.7%), 
644,447 (11.4%), and 1,434,122 (25.3%) were categorized into the MHNO, MUNO, MHO, 
and MUO groups, respectively. The mean age was 67.1 years, 45.7% were male, and mean 
BMI was 24.1 kg/m2.  
Figure 1 shows the distribution by ATP-III criteria for metabolic syndrome in the four 
groups. All parameters showed higher prevalence in the metabolically unhealthy groups than 
in the metabolically healthy groups. Of these, the most common ATP-III criterion for 
metabolic syndrome was high blood pressure (69.3%), followed by hyperglycemia (54.8%), 
hypertriglyceridemia (49.2%), and low HDL cholesterol (43.6%).  
Risk of incident dementia according to metabolic health and obesity status  
During 29,089,302 person-years of follow-up, a total of 363,932 subjects (6.4%) developed 
incident dementia. Among them, 267,368 (73.5%) had AD and 43,918 (12.1%) had VaD. The 
crude incidence rate of overall dementia was 5.7% (99,538/1,738,074) in the MHNO group, 
8.1% (150,341/1,852,845) in the MUNO group, 4.3% (27,675/644,447) in the MHO group, 
and 6.0% (86,378/1,434,122) in the MUO group. Figure 2 shows the Kaplan-Meier curves for 
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overall dementia-free survival for each group. Individuals in the MHO group had the lowest 
probabilities of developing incident dementia, and the probabilities increased sequentially for 
the MHNO, MUO, and MUNO group (log rank p<0.001).  
The incidence rates (number of events per 1,000 person-years) and HRs of overall 
dementia, AD, and VaD according to metabolic health and obesity status are demonstrated in 
Table 2. Adjusted HR (95% CI) of the MUNO, MHO, and MUO groups for incident overall 
dementia were 1.16 (1.15-1.17), 0.85 (0.84-0.86), and 1.01 (0.99-1.02) compared with 
MHNO group after adjustment for age, sex, tobacco and alcohol use, exercise level, 
socioeconomic status, and LDL-cholesterol (model 3). With regard to the subtypes of 
dementia, subjects in the MHO group showed a significantly lower HR for AD, compared 
with the MHNO group; however, a protective effect was not observed in VaD. In addition, 
those who were metabolically unhealthy were associated with increased dementia risk, and 
this effect was more prominent in VaD than AD, demonstrating a 30%-40% risk elevation. 
There was no gender-related difference in the incidence of dementia (data not shown).  
Furthermore, we conducted subgroup analyses by dividing the subjects according to 
smoking, drinking, and exercise status: (1) subjects without modifiable risk factors (both non-
current smoker, no heavy drinker, and physically active; n = 1,978,111) and (2) subjects with 
modifiable risk factors (both current smoker, heavy drinker, and not physically active; n = 
60,564). Consistent with the main results, the MHO group showed the lowest incidence of 
overall dementia and AD; incident VaD was not affected, regardless of the presence of 
modifiable risk factors (Table 3). In particular, the protective effect of the MHO on the 
development of AD was more prominent in the dementia-prone individuals with risk factors 
(HR 0.71 in the group with risk factors vs. 0.88 in the group with no risk factors).  
Impact of metabolic syndrome and its components on the risk of incident dementia  
Next, we examined the association between BMI, components of metabolic syndrome, and 
incident dementia (Table 4). Compared with non-obese subjects, obese individuals had 
decreased risk of overall dementia (HR 0.90, 95% CI 0.89-0.91) and AD (HR 0.88, 95% CI 
0.87-0.89), but obesity had no beneficial impact on VaD (HR 1.01, 95% CI 0.99-1.03). All 
metabolic syndrome criteria (high BP, hyperglycemia, high triglyceride, and low HDL 
cholesterol) were significantly associated with the development of dementia regardless of 
type, and these associations were more pronounced in VaD. Meeting 2 or more criteria for 
metabolic syndrome was also highly correlated with the development of overall dementia, 
and the adjusted HR was significantly higher in VaD compared to AD (HR 1.37 vs 1.14). 
Supplementary analyses 
A sensitivity analysis (exclusion of underweight subjects with BMI <18.5 kg/m2) revealed 
that the MHO group showed decreased risks of overall dementia and AD, but lost statistical 
significance in VaD (Table 5). However, the risk of dementia was increased in the MUO 
group, while it decreased in the MUNO group, suggesting that being underweight contributes 
significantly to the development of dementia. 
Similar patterns were noted for subjects aged 50-60 years (n = 6,627,375), although the 
protective effect of MHO phenotype on overall dementia was smaller than that in subjects 
aged over 60 (Table 6, 7). Additionally, the MUO group of individuals aged 50-60 years 
showed a much higher risk of VaD than those aged over 60 years (HR 1.71 vs 1.33), 
suggesting that metabolic abnormalities have a greater impact on the incidence of dementia in 
middle-aged individuals.  
Discussion  
In this longitudinal nationwide study, we analyzed the risk of incident dementia according to 
late-life metabolic health and obesity status. Among four groups, subjects with MHO showed 
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the lowest incidences of overall dementia and AD but had no impact on the development of 
VaD. Furthermore, the protective effect of the MHO on AD was maintained in both high risk 
and low risk group, excluding underweight subjects, and in middle-age individuals, although 
the degree was different. Of component, unhealthy metabolic profiles were positively 
associated with incident dementia, particularly in VaD, and obesity was associated with lower 
risk on the development of AD.  
With respect to the impact of metabolic status on dementia, our study revealed that 
having two or more metabolic abnormalities was associated with development of both AD 
and VaD. This effect was more prominent in VaD, with a 41% greater risk in MUNO 
subjects compared to non-obese MHNO subjects, and a 31% greater risk in MUO subjects 
compared to non-obese MHO subjects. Furthermore, all criteria for metabolic syndrome 
(high BP, high glycemia, high triglycerides and low HDL cholesterol) were associated with 
an increased risk of incident dementia.  
Hypertension is reported to increase the risk of incident VaD 2.0 to 4.6-fold in female 
subjects but the HR in male subjects was not statistically significant (28, 29). However, a 
meta-analysis of six longitudinal studies demonstrated that hypertension is associated with 
VaD (odds ratio 1.59, 95% CI 1.29-1.95) (30). Our findings are consistent with the latter that 
high BP is associated with VaD (HR 1.44, 95% CI 1.41-1.48). DM is also a well-known risk 
factor for incident dementia, increasing risk 1.5 to 2.0-fold; the impact was evident in the 
development of VaD, showing a HR of 2.0-2.5, but its relationship to AD was not consistent 
(31-34). In our study, hyperglycemia increased the risk of overall dementia and AD 1.2-fold, 
and raised the risk of VaD 1.3-fold. The impact on VaD was less than expected, probably 
because we defined hyperglycemia as including both prediabetes and diabetes (either FPG 
≥100 mg/dL or on antidiabetic treatment), while previous studies were conducted in only 
patients with diabetes. Regarding hyperlipidemia and dementia, the published findings are 
inconsistent (34-37). However, in our large-scale analyses, both high triglycerides and low 
HDL cholesterol were associated with a 6%-16% increased risk of dementia. The inconsistent 
results may be explained by differences in study design, such as age or ethnicity of 
participants, and different definitions of hyperlipidemia.  
Previous studies investigating the association between obesity and the development of 
dementia reported that midlife obesity was associated with a 1.7 to 2.0-fold increased risk of 
incident dementia (12, 38). In contrast, most recent studies revealed that being overweight or 
obese in old age is protective for dementia development (13, 14, 39-41). Regarding mortality, 
overweight subjects with AD showed a longer survival compared to those with normal 
weight (42). Our study results are in line with previous study results showing significant risk 
reduction of AD in old obese subjects. These results are consistent with the hypothesis of the 
‘obesity paradox’ in which overweight or obese subjects are predicted to have lower 
mortality than normal weight subjects in various established disease cohorts (43-45). When 
we further analyzed the effect of metabolic health and obesity status on the development of 
dementia in subjects aged 50-60 years, the MHO group consistently demonstrated the lowest 
incidence of overall dementia and AD, but to a lesser extent than that in subjects aged 60 
years and older. In addition, when underweight subjects were excluded in the analysis, the 
risk of dementia increased in the MUO group, whereas the risk in the MUNO group 
decreased, suggesting that being underweight had a great impact on the incidence of 
dementia.  
There are several possible mechanisms explaining the beneficial role of MHO regarding 
development of dementia. First, unintentional weight loss in the elderly is usually associated 
with malnutrition and coexisting chronic diseases (46). Actually, many studies have 
demonstrated that weight loss precedes the diagnosis of dementia by 10 years (47, 48). 
Second, plasma insulin-like growth factor I (IGF-1) levels decline in the underweight group 
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(49). By exerting neurotrophic activities in the hippocampus, it is associated with better 
cognitive performance (50), and decreased serum IFG-1 level turned out to be an independent 
risk factor for AD and VaD (51). Third, adipokines secreted from adipose tissue may play a 
role (52). A higher circulating leptin level is associated with a higher cerebral brain volume, 
including the hippocampus, and is inversely correlated with cognitive impairment and 
incident dementia (53, 54). Fourth, persistent organic pollutants (POPs) such as 
polychlorinated biphenyls or polychlorinated dibenzofurans have been reported to cause 
various toxic effects, especially in neurocognitive function (55, 56). Exposure to POPs was 
associated with dose-dependent deterioration of attention, memory and learning ability (57, 
58), which suggests potential links to dementia. As POPs are usually lipophilic and are 
distributed in adipose tissue, serum concentrations increase after weight loss with 
redistribution to tissues such as brain (59) .   
Our study has several limitations. First, dementia and other comorbidities were identified 
using claims data from the NHIS database. There is a possibility of coding errors or under- or 
over-estimation. To avoid overestimation and to raise diagnostic accuracy, we defined 
dementia using both ICD-10 codes and history of prescription anti-dementia drugs. The 
incidence rate of overall dementia (12.5 per 1000 person-years) reported in this study is 
consistent to the rates reported in previous studies in China, Japan, and Europe (60-62), 
which raise reliability of our study. Second, BMI or metabolic status can change over time in 
a substantial proportion of the population, however, our study did not reflect the longitudinal 
changes of body weight or laboratory findings. Third, as the mean BMI of MHO group was 
27.0 kg/m2, the study results may not be generalized to a more severely obese group. Fourth, 
despite this longitudinal study design, our findings cannot be used to make causal inferences. 
Further prospective are needed to determine metabolic health and obesity status as 
predisposing factors for dementia. Fifth, the information about apolipoprotein E4 phenotype, 
educational level, vitamin B12 and vitamin D status, and thyroid function test was not 
available. Despite these limitations, this is the first study to investigate the risk of incident 
dementia among different metabolic phenotypes in older adults. We analyzed a nationwide 
population over 29,089,304 person-years of follow-up. The large sample size provided 
statistical power to demonstrate associations between metabolic health and obesity status and 
dementia.  
In summary, the present study illustrated different risks for dementia according to 
metabolic health and obesity status in late life using an Asian population-based cohort. The 
MHO phenotype showed a 13-15% lower risk of overall dementia and AD, compared to the 
MHNO phenotype, but no difference in the incidence of VaD. Increased dementia incidence 
in the metabolically unhealthy group was more prominent in VaD and risk reduction in obese 
group was evident in AD. Further studies in other populations are warranted, to better 
understand the effect of metabolic health status and obesity on dementia.  
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Figure 1. Distribution of metabolic syndrome criteria by metabolic health and obesity 
status. Abbreviations: BP, blood pressure; TG, triglyceride; HDL-C, high density lipoprotein 
cholesterol; MHNO, metabolically healthy non-obese; MUNO, metabolically unhealthy non-
obese; MHO, metabolically healthy obese; MUO, metabolically unhealthy obese. 
Figure 2. Dementia-free survival by Kaplan-Meier. A. Overall dementia. B. Alzheimer’s 
disease. C. Vascular dementia. Subjects were followed for a median of 65 months 
(interquartile range 51-74 months). Cumulative dementia-free probability is presented in the 
y-axis. Plots use different y-axis scale. Abbreviations: MHNO, metabolically healthy non-
obese; MUNO, metabolically unhealthy non-obese; MHO, metabolically healthy obese; 
MUO, metabolically unhealthy obese. 
Table 1. Baseline characteristics of study subjects according to metabolic healthy and obesity  
Characteristic Non-obese (n = 3,590,919) Obese (n = 2,078,569) 
MHNO (n = 
1,738,074) 
MUNO (n = 
1,852,845) 
MHO (n = 644,447) MUO (n = 
1,434,122) 
Age, y 66.8 ± 6.4 68.1 ± 6.8 65.8 ± 5.6 66.9 ± 6.0 
Male sex  867,637 (49.9) 865,703 (46.7) 263,261 (40.9) 595,782 (41.5) 
Height, cm 158.9 ± 8.6 158.3 ± 8.8 157.7 ± 8.6 157.8 ± 8.8 
Weight, kg 55.6 ± 7.9 56.8 ± 8.0 67.3 ± 8.1 68.4 ± 8.6 
BMI, kg/m2 22.0 ± 2.0 22.6 ± 1.8 27.0 ± 1.8 27.4 ± 2.1 
Systolic BP, mmHg 122.3 ± 14.8 132.0 ± 15.6 126.1 ± 14.7 133.6 ± 15.2 
Diastolic BP, mmHg 75.0 ± 9.5 79.4 ± 9.9 77.2 ± 9.5 80.5 ± 9.8 
Fasting glucose, mg/dL 92.8 ± 16.0 111.0 ± 30.9 93.1 ± 14.4 112.0 ± 29.6 
Total cholesterol, mg/dL 196.6 ± 36.2 197.5 ± 40.4 201.6 ± 36.9 200.4 ± 40.6 
Triglyceride, mg/dL  98.3 ± 42.5 163.2 ± 93.9 106.4 ± 43.7 175.2 ± 95.4 
HDL-C, mg/dL 59.0 ± 17.7 50.3 ± 17.7 57.7 ± 17.3 49.2 ± 17.0 
LDL-C, mg/dL 118.2 ± 33.4 115.4 ± 36.9 122.8 ± 34.3 117.1 ± 37.4 
Current smoker 285,388 (16.4) 293,240 (15.8) 59,865 (9.3) 150,405 (10.5) 
Heavy drinker   68,470 (3.9) 92,641 (5.0) 20,785 (3.2) 61,843 (4.3) 
Exercise 759,858 (43.7) 750,817 (40.5) 284,349 (44.1) 585,875 (40.9) 
Low SES  384,236 (22.1) 414,186 (22.4) 139,787 (21.7) 315,948 (22.0) 
Comorbidities      
Hypertension   484,857 (27.9) 1,234,184 (66.6) 262,942 (40.8) 1,086,237 (75.7) 
Diabetes  75,192 (4.3) 539,691 (29.1) 26,257 (4.1) 469,584 (32.7) 
Hyperlipidemia  149,566 (8.6) 253,593 (13.7) 67,287 (10.4) 212,404 (14.8) 
CKD  162,082 (9.3) 285,461 (15.4) 72,966 (11.3) 247,832 (17.3) 
Previous myocardial infarction 77,872 (4.5) 127,374 (6.9) 37,534 (5.8) 116,146 (8.1) 
Previous ischemic stroke    80,878 (4.7) 144,502 (7.8) 33,838 (5.3) 111,809 (7.8) 
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Values are presented as mean (standard deviation) for continuous variables and n (%) for categorical variables. 
Abbreviations: MHNO, metabolically healthy non-obese; MUNO, metabolically unhealthy non-obese; MHO, 
metabolically healthy obese; MUO, metabolically unhealthy obese; BMI, body mass index; BP, blood pressure; 
HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; SES, socioeconomic 
status; CKD, chronic kidney disease  
Table 2. Hazard ratios for the development of dementia according to metabolic health and 
obesity status  
Group  Incident 
cases, n 
Person-years, 
n  
Incident 
rate*  
Model 1†  Model 2‡ Model 3§  
Overall dementia   
  MHNO  99,538 8,928,576 11.1 1 (ref)  1 (ref) 1 (ref) 
  MUNO 150,341 9,386,923 16.0 1.44 (1.43-1.45) 1.20 (1.19-1.21) 1.16 (1.15-1.17) 
  MHO  27,675 3,364,116 8.2 0.74 (0.73-0.75) 0.86 (0.84-0.87) 0.85 (0.84-0.86) 
  MUO  86,378 7,409,687 11.7 1.05 (1.04-1.06) 1.04 (1.03-1.05) 1.01 (0.99-1.02) 
Alzheimer’s disease  
  MHNO  74,340 8,928,576 8.3 1 (ref) 1 (ref) 1 (ref) 
  MUNO 110,318 9,386,923 11.8 1.41 (1.40-1.43) 1.16 (1.15-1.18) 1.38 (1.35-1.42) 
  MHO  20,254 3,364,116 6.0 0.72 (0.71-0.73) 0.84 (0.83-0.85) 0.87 (0.86-0.88) 
  MUO  62,456 7,409,687 8.4 1.01 (1.00-1.02) 1.00 (0.99-1.02) 1.29 (1.25-1.32) 
Vascular dementia   
  MHNO 10,701 8,928,576 1.2 1 (ref) 1 (ref) 1 (ref) 
  MUNO 18,235 9,386,923 1.9 1.62 (1.59-1.66) 1.42 (1.38-1.45) 1.41 (1.38-1.44) 
  MHO 3,487 3,364,116 1.0 0.86 (0.83-0.90) 0.99 (0.96-1.03) 1.02 (0.98-1.06) 
  MUO  11,495 7,409,687 1.6 1.29 (1.26-1.33) 1.32 (1.28-1.35)  1.33 (1.29-1.36) 
Abbreviations: MHNO, metabolically healthy non-obese; MUNO, metabolically unhealthy non-obese; MHO, 
metabolically healthy obese; MUO, metabolically unhealthy obese 
*Incident rate for 1000 person-years 
†Unadjusted  
‡Adjusted for age and sex   
§Further adjusted for tobacco and alcohol use, exercise, socioeconomic status, and low density lipoprotein-
cholesterol 
Values with statistical significance are printed in bold.  
Table 3. Contribution of metabolic health and obesity status on the development of dementia 
according to the presence of modifiable risk factors  
Group  Without modifiable risk factors*  With modifiable risk factors†  
Model 1‡ Model 2§  Model 1‡ Model 2§  
Overall dementia   
  MHNO  1 (ref)  1 (ref) 1 (ref)  1 (ref) 
  MUNO 1.07 (1.06-1.09) 1.05 (1.03-1.07) 0.77 (0.68-0.86) 1.00 (0.89-1.12) 
  MHO  0.79 (0.77-0.81) 0.89 (0.87-0.92) 0.65 (0.53-0.79) 0.81 (0.67-0.98) 
  MUO  1.42 (1.40-1.44) 1.18 (1.16-1.20) 1.23 (1.14-1.33) 1.32 (1.23-1.43) 
Alzheimer’s disease  
  MHNO  1 (ref) 1 (ref) 1 (ref) 1 (ref) 
  MUNO 1.03 (1.01-1.05) 1.00 (0.98-1.03) 0.75 (0.65-0.86) 1.00 (0.87-1.15) 
  MHO  0.78 (0.76-0.80) 0.88 (0.86-0.91) 0.55 (0.43-0.71) 0.71 (0.55-0.91) 
  MUO  1.39 (1.37-1.42) 1.15 (1.13-1.17) 1.17 (1.06-1.28) 1.26 (1.15-1.38) 
Vascular dementia   
  MHNO 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
  MUNO 1.41 (1.34-1.48) 1.39 (1.32-1.46) 0.97 (0.74-1.27) 1.19 (0.91-1.56) 
  MHO 0.97 (0.90-1.04) 1.07 (1.00-1.15) 0.77 (0.48-1.22) 0.91 (0.57-1.45) 
  MUO  1.66 (1.58-1.74) 1.43 (1.37-1.51) 1.44 (1.19-1.75) 1.52 (1.25-1.85) 
Abbreviations: MHNO, metabolically healthy non-obese; MUNO, metabolically unhealthy non-obese; MHO, 
metabolically healthy obese; MUO, metabolically unhealthy obese 
* Subjects of both non-current smoker, not heavy drinker, and physically active 
† Subjects of both current smoker, heavy drinker, and not physically active 
‡ Unadjusted 
§ Adjusted for age, sex, socioeconomic status, and low density lipoprotein-cholesterol 
Values with statistical significance are printed in bold.  
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/jc.2018-01491/5364430 by YO
N
SEI U
N
IVER
SITY M
ED
IC
AL LIBR
AR
Y user on 27 February 2019
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2018-01491 
 
 
14
Table 4. Hazard ratios for developing dementia according to obesity status and metabolic 
syndrome criteria  
Criteria Overall dementia  Alzheimer’s disease  Vascular dementia  
n Adjusted HR* 
(95% CI) 
n Adjusted HR* 
(95% CI) 
n Adjusted HR* 
(95% CI) 
Obesity† 
No (n = 3,590,919) 249,879 1 (ref) 184,658 1 (ref)  28,936 1 (ref) 
Yes (n = 2,078,569) 114,053 0.90 (0.89-0.91)  82,710 0.88 (0.87-0.89)  14,982 1.01 (0.99-1.03) 
High blood pressure‡ 
No (n = 1,737,573)  86,464 1 (ref)  65,197 1 (ref)   8,800 1 (ref) 
Yes (n = 3,931,915) 277,468 1.10 (1.09-1.11) 202,171 1.05 (1.04-1.06)  35,118 1.44 (1.41-1.48)  
Hyperglycemia§ 
No (n = 3,053,488) 178,572 1 (ref) 132,326 1 (ref)  20,711 1 (ref) 
Yes (n = 2,616,000) 185,360 1.21 (1.20-1.22) 135,042 1.19 (1.18-1.20)  23,207 1.30 (1.28-1.33) 
High triglycerides∥ 
No (n = 3,807,141) 238,245 1 (ref) 175,715 1 (ref)  28,040 1 (ref) 
Yes (n = 1,862,347) 125,687 1.07 (1.06-1.08)  91,653 1.06 (1.05-1.07)  15,878 1.15 (1.13-1.17) 
Low HDL cholesterol 
No (n = 4,059,350) 239,860 1 (ref) 175,794 1 (ref)  29,029 1 (ref) 
Yes (n = 1,610,138) 124,072 1.08 (1.07-1.09)  91,574 1.07 (1.06-1.08)  14,889 1.16 (1.14-1.18)  
Metabolic syndrome** 
No (n = 2,382,521) 127,213 1 (ref)  94,594 1 (ref)  14,188 1 (ref) 
Yes (n = 3,286,967) 236,719 1.18 (1.17-1.19) 172,774 1.14 (1.13-1.15)  29,730  1.37 (1.35-1.40)  
Abbreviations: HR, hazard ratio; CI, confidence interval  
*Adjusted for age, sex, tobacco and alcohol use, exercise, and socioeconomic status 
†Body mass index (BMI) 25 kg/m2  
‡Systolic blood pressure 130 mmHg or diastolic blood pressure 85 mmHg or on antihypertensive 
medication  
§Fasting plasma glucose 100 mg/dL or on anti-diabetic medication  
∥Triglycerides 150 mg/dL 
¶High-density lipoprotein cholesterol <40 mg/dL in males or <50 mg/dL in females  
**Meet 2 or more of metabolic syndrome criteria 
Values with statistical significance are printed in bold.  
Table 5. Sensitivity analysis for the development of dementia after exclusion of underweight 
individuals   
Group  Incident 
cases, n 
Person-years, 
n  
Incident 
rate*  
Model 1†  Model 2‡ Model 3§  
Overall dementia   
  MHNO  88,406 8,401,410 10.5 1 (ref)  1 (ref) 1 (ref) 
  MUNO 141,267 9,128,208 15.5 1.11 (1.10-1.12) 1.07 (1.06-1.08) 1.07 (1.06-1.08) 
  MHO  27,675 3,364,116 8.2 0.78 (0.77-0.79) 0.88 (0.87-0.89) 0.88 (0.88-0.90) 
  MUO  86,378 7,409,687 11.7 1.47 (1.46-1.49) 1.21 (1.20-1.22) 1.21 (1.20-1.22) 
Alzheimer’s disease  
  MHNO  65,867 8,401,410 7.8 1 (ref) 1 (ref) 1 (ref) 
  MUNO 103,566 9,128,208 11.3 1.08 (1.06-1.09) 1.03 (1.02-1.04) 1.03 (1.02-1.04) 
  MHO  20,254 3,364,116 6.0 0.77 (0.76-0.78) 0.86 (0.85-0.88) 0.87 (0.86-0.88) 
  MUO  62,456 7,409,687 8.4 1.45 (1.44-1.47) 1.18 (1.17-1.19) 1.17 (1.16-1.19) 
Vascular dementia   
  MHNO 9643 8,401,410 1.2 1 (ref) 1 (ref) 1 (ref) 
  MUNO 17,282 9,128,208 1.9 1.35 (1.32-1.39) 1.34 (1.30-1.38) 1.35 (1.31-1.38) 
  MHO 3487 3,364,116 1.0 0.90 (0.87-0.94) 1.01 (0.97-1.05) 1.03 (0.99-1.07) 
  MUO  11,495 7,409,687 1.6 1.65 (1.61-1.69) 1.42 (1.39-1.46) 1.42 (1.38-1.45) 
Abbreviations: MHNO, metabolically healthy non-obese; MUNO, metabolically unhealthy non-obese; MHO, 
metabolically healthy obese; MUO, metabolically unhealthy obese 
*Incident rate for 1000 person-years 
†Unadjusted  
‡Adjusted for age and sex   
§Further adjusted for tobacco and alcohol use, exercise, socioeconomic status, and low density lipoprotein-
cholesterol 
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Values with statistical significance are printed in bold.  
Table 6. Baseline characteristics of study subjects according to metabolic healthy and obesity 
in subjects aged 50-60 years 
Characteristic Non-obese (n = 4,270,579) Obese (n = 2,356,796) 
MHNO (n = 
3,282,724) 
MUNO (n = 
987,855) 
MHO (n = 
1,024,260) 
MUO (n = 
1,332,536) 
Age, y 53.5 ± 3.3 54.6 ± 3.4 53.7 ± 3.3 54.4 ± 3.4 
Male sex  1,468,731 (44.7) 454,427 (46.0) 546,028 (53.3) 695,994 (52.2) 
Height, cm 161.5 ± 8.0 161.6 ± 8.2 161.9 ± 8.4 162.3 ± 8.7 
Weight, kg 58.1 ± 7.6 60.4 ± 7.5 70.2 ± 8.0 72.9 ± 9.2 
BMI, kg/m2 22.2 ± 1.8 23.1 ± 1.5 26.78 ± 1.7 27.6 ± 2.2 
Systolic BP, mmHg 119.5 ± 14.1 128.9 ± 14.8 123.3 ± 13.8 131.0 ± 14.6 
Diastolic BP, mmHg 74.9 ± 9.7 80.2 ± 10.0 77.4 ± 9.6 81.8 ± 9.9 
Fasting glucose, mg/dL 94.9 ± 19.1 112.8 ± 34.7 95.3 ± 17.2 111.8 ± 31.4 
Total cholesterol, mg/dL 200.0 ± 34.5 205.9 ± 43.8 204.2 ± 34.2 206.4 ± 41.5 
Triglyceride, mg/dL  98.1 ± 17.2 161.2 ± 18.9 109.8 ± 18.2 169.4 ± 18.8 
HDL-C, mg/dL 58.3 ± 15.7 51.1 ± 16.2 55.6 ± 15.4 49.6 ± 15.8 
LDL-C, mg/dL 119.9 ± 31.9 118.9 ± 41.1 124.5 ± 31.8 119.5 ± 38.9 
Current smoker 675,096 (20.6) 222,377 (22.5) 186,371 (18.2) 273,367 (20.5) 
Heavy drinker   174,917 (5.3) 74,104 (7.5) 67,816 (6.6) 117,302 (8.8) 
Exercise 1,688,721 (51.4) 490,834 (49.7) 540,187 (52.7) 658,377 (49.4) 
Low SES  723,132 (22.0) 227,418 (23.0) 215,868 (21.1) 299,117 (22.5) 
Comorbidities      
Hypertension   569,118 (17.3) 541,839 (54.9) 256,199 (25.0) 821,072 (61.6) 
Diabetes  154,171 (4.7) 256,067 (25.9) 48,092 (4.7) 341,823 (25.7) 
Hyperlipidemia  458,779 (14.0) 539,040 (54.6) 155,503 (15.2) 638,897 (48.0) 
CKD  111,024 (3.4) 52,927 (5.4) 36,746 (3.6) 70,943 (5.3) 
Previous myocardial infarction 40,662 (1.2) 40,868 (4.1) 14,702 (1.4) 55,136 (4.1) 
Previous ischemic stroke    41,234 (1.3) 35,804 (3.6) 14,855 (1.4) 45,748 (3.4) 
Values are presented as mean (standard deviation) for continuous variables and n (%) for categorical variables. 
Abbreviations: MHNO, metabolically healthy non-obese; MUNO, metabolically unhealthy non-obese; MHO, 
metabolically healthy obese; MUO, metabolically unhealthy obese; BMI, body mass index; BP, blood pressure; 
HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; SES, socioeconomic 
status; CKD, chronic kidney disease  
Table 7. Hazard ratios for the development of dementia according to metabolic health and 
obesity status in subjects aged 50-60 years 
Group  Incident 
cases, n 
Person-years, 
n  
Incident 
rate*  
Model 1†  Model 2‡ Model 3§  
Overall dementia   
  MHNO  12,678 17,056,868 0.7 1 (ref)  1 (ref) 1 (ref) 
  MUNO 6611 5,171,781 1.3 1.38 (1.34-1.43) 1.19 (1.16-1.23) 1.19 (1.16-1.23) 
  MHO  3601 5,356,227 0.7 0.90 (0.87-0.94) 0.88 (0.85-0.91) 0.90 (0.87-0.93) 
  MUO  7188 6,962,901 1.0 1.71 (1.66-1.76) 1.42 (1.28-1.46) 1.41 (1.37-1.45) 
Alzheimer’s disease  
  MHNO  7903 17,056,868 0.5 1 (ref) 1 (ref) 1 (ref) 
  MUNO 3967 5,171,781 0.8 1.31 (1.26-1.36) 1.11 (1.07-1.16) 1.11 (1.07-1.16) 
  MHO  2184 5,356,227 0.4 0.88 (0.84-0.92) 0.86 (0.82-0.90) 0.88 (0.83-0.92) 
  MUO  4252 6,962,901 0.6 1.65 (1.58-1.71) 1.33 (1.28-1.38) 1.33 (1.28-1.38) 
Vascular dementia   
  MHNO 2437 17,056,868 0.1 1 (ref) 1 (ref) 1 (ref) 
  MUNO 1467 5,171,781 0.3 1.72 (1.61-1.83) 1.52 (1.43-1.62) 1.53 (1.44-1.63) 
  MHO 769 5,356,227 0.1 1.00 (0.92-1.08) 0.97 (0.89-1.05) 0.99 (0.92-1.08) 
  MUO  1713 6,962,901 0.2 1.98 (1.85-2.11) 1.73 (1.62-1.84) 1.71 (1.60-1.82) 
Abbreviations: MHNO, metabolically healthy non-obese; MUNO, metabolically unhealthy non-obese; MHO, 
metabolically healthy obese; MUO, metabolically unhealthy obese 
*Incident rate for 1000 person-years 
†Unadjusted  
‡Adjusted for age and sex   
§Further adjusted for tobacco and alcohol use, exercise, socioeconomic status, and low density lipoprotein-
cholesterol 
Values with statistical significance are printed in bold.  
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